Selvigaltin (GB1211), an orally accessible small molecule galectin-3 inhibitor developed for a remedy for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and security to handle regulatory requirements. Inhibition of galectin-three with GB1211 wasn't related to any treatment- or dose-related tendencies and https://selvigaltin-gb121124578.topbloghub.com/45797449/the-definitive-guide-to-selvigaltin-gb1211